Last update 18 Nov 2024
Amlodipine Besylate/Atorvastatin Calcium
Last update 18 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Amlodipine Besilate/Atorvastatin Calcium Hydrate, Amlodipine Besylate/Atorvastatin Calcium Hydrate, Amlodipine/atorvastatin + [6] |
Mechanism HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), VDCCs blockers(Voltage-gated calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (30 Jan 2004), |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC33H35CaFN2O5 |
InChIKeyBWFCZHDTTAYGNN-CNZCJKERSA-N |
CAS Registry134523-03-8 |
View All Structures (3)
Related
56
Clinical Trials associated with Amlodipine Besylate/Atorvastatin Calcium氨氯地平阿托伐他汀钙片在中国成年健康受试者中的一项单中心、随机、开放、空腹和餐后单次给药、两制剂、三序列、三周期部分重复交叉生物等效性研究
[Translation] A single-center, randomized, open-label, single-dose, fasting and postprandial, two-formulation, three-sequence, three-period partially repeated crossover bioequivalence study of amlodipine and atorvastatin calcium tablets in healthy Chinese adult subjects
氨氯地平阿托伐他汀钙片在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、三序列、三周期、部分重复交叉生物等效性试验
[Translation] A randomized, open-label, single-dose, three-sequence, three-period, partially repeated crossover bioequivalence study of amlodipine and atorvastatin calcium tablets in Chinese healthy volunteers under fasting and fed conditions
氨氯地平阿托伐他汀钙片在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、三序列、三周期、部分重复交叉生物等效性试验
[Translation] A randomized, open-label, single-dose, three-sequence, three-period, partially repeated crossover bioequivalence study of amlodipine and atorvastatin calcium tablets in Chinese healthy volunteers under fasting and fed conditions
100 Clinical Results associated with Amlodipine Besylate/Atorvastatin Calcium
Login to view more data
100 Translational Medicine associated with Amlodipine Besylate/Atorvastatin Calcium
Login to view more data
100 Patents (Medical) associated with Amlodipine Besylate/Atorvastatin Calcium
Login to view more data
14
Literatures (Medical) associated with Amlodipine Besylate/Atorvastatin Calcium01 Dec 2014BMC ophthalmologyQ4 · MEDICINE
Chronic unilateral chemosis following the use of amlodipine besylate
Q4 · MEDICINE
ArticleOA
Author: Wan Soo Kim ; Kyeong Hwan Kim
BACKGROUND:
This case report describes a patient with chronic unilateral chemosis, likely due to treatment with amlodipine besylate.
CASE PRESENTATION:
A 52-year-old man visited the clinic with symptoms of foreign body sensation and puffiness in his right eye, which had persisted for 4 months. There were no other symptoms, such as itching and pain, in his right eye and no specific symptoms in his left eye. He had been treated for hypertension and hyperlipidemia for the previous 5 months with once daily amlodipine besylate/atorvastatin (Caduet) and candesartan cilexetil (Atacand). Examination revealed marked swelling of the inferior bulbar conjunctiva in the right eye. Evaluation revealed no specific causes for the longstanding chemosis. A change of medication to telmisartan/hydrochlorothiazide (Micardis Plus) without amlodipine besylate resulted in significant improvements in his symptoms after 1 month and complete remission after 8 months.
CONCLUSION:
Prior to invasive evaluation including biopsy, specific drugs should be considered as possible causes of idiopathic longstanding conjunctival chemosis.
01 Jan 2013Analytical chemistry insights
Simultaneous Determination of Amlodipine Besylate and Atorvastatin Calcium in Binary Mixture by Spectrofluorimetry and HPLC Coupled with Fluorescence Detection
Article
Author: Ahmed, Maha S. ; Mahrouse, Marianne A. ; Moussa, Bahia A. ; El-Zaher, Asmaa A.
Caduet tablets are novel prescription drug that combines amlodipine besylate (AM) with atorvastatin calcium (AT). A spectrofluorimetric and an HPLC-fluorescence detection methods were developed for simultaneous determination of both drugs in tablets. In the spectrofluorimetric method, native fluorescence of AM and AT were measured in methanol at 442 and 369 nm upon excitation at 361 and 274 nm, respectively. The emission spectrum of each drug reveals zero value at the emission wavelength of the other drug, thus allowing their simultaneous determination without interference. In the HPLC method, separation of AM and AT was achieved within 8 minutes on a C18column using acetonitrile:phosphate buffer (0.015 M, pH 3) (45:55, v/v) as the mobile phase. Fluorescence detection was carried out using excitation wavelengths 361 and 274 nm and emission wavelengths 442 and 378 nm for AM and AT, respectively. Excellent linearity was observed. Careful validation proved advantages of the new methods: high sensitivity, accuracy, selectivity and suitability for quality control laboratories.
01 Jan 2013Advances in therapyQ3 · MEDICINE
Slovak Trial on Cardiovascular Risk Reduction Following National Guidelines with CaDUET® (The STRONG DUET Study)
Q3 · MEDICINE
Article
Author: Lucia Merkovska ; Peter Jarcuska ; Jan Fedacko ; Martin Janicko ; Matej Sajty ; Tomas Lopuchovsky ; Lucia Jedlickova ; Jan Kmec ; Daniel Pella ; Frantisek Sabol
INTRODUCTION:
The efficacy and safety of single-pill amlodipine/atorvastatin for reducing blood pressure (BP), low-density lipoprotein cholesterol (LDLC), and predicted 10-year cardiovascular (CV) risk have been demonstrated in low CV risk countries. The Slovak Trial on Cardiovascular Risk Reduction Following National Guidelines with CaDUET® (amlodipine besylate/atorvastatin calcium; Pfizer, Morrisville, PA, USA; STRONG DUET) study evaluated its clinical utility in Slovakia, one of the highest CV risk regions in Europe.
METHODS:
This was a two-phase study involving 100 outpatient cardiologist and internist departments in Slovakia. Phase 1 assessed BP control and CV risk profiles in adults with treated hypertension, and phase 2 was an open-label, multicenter, observational study. In the phase 2 study, patients with treated but uncontrolled hypertension and three or more coronary heart disease risk factors received single-pill amlodipine/atorvastatin (5/10 or 10/10 mg) for 12 weeks. Major outcomes were the percentage of patients achieving target BP (≤140/90 mmHg) and/or LDL-C (≤3 mmol/L) and reductions in predicted 10-year CV risk.
RESULTS:
Of the 4,672 phase 1 patients, 80.8% had uncontrolled hypertension and 61.4% had dyslipidemia. Of the 1,406 phase 2 patients, 90.3% of patients achieved target BP at week 12, 66.3% achieved target LDL-C, and 60.7% achieved both. The mean 10-year CV risk was reduced by 49% (P < 0.0001); treatment was well-tolerated and safe.
CONCLUSION:
Single-pill amlodipine/atorvastatin was associated with significant improvements in BP, LDL-C target attainment, and 10-year CV risk in patients with uncontrolled hypertension in Slovakia. The treatment was well-tolerated and safe. Use of single-pill amlodipine/atorvastatin in high CV-risk countries could lead to significant improvements in CV risk management.
100 Deals associated with Amlodipine Besylate/Atorvastatin Calcium
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Amlodipine Besylate/Atorvastatin Calcium | - |
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hyperlipoproteinemia Type II | JP | 07 Jul 2009 | |
| Angina Pectoris | CN | 03 Apr 2008 | |
| Coronary Disease | CN | 03 Apr 2008 | |
| Hypercholesterolemia | CN | 19 Apr 2005 | |
| Angina Pectoris, Variant | US | 30 Jan 2004 | |
| Angina, Stable | US | 30 Jan 2004 | |
| Heterozygous familial hypercholesterolemia | US | 30 Jan 2004 | |
| Homozygous familial hypercholesterolemia | US | 30 Jan 2004 | |
| Hyperlipoproteinemia Type III | US | 30 Jan 2004 | |
| Hypertension | US | 30 Jan 2004 | |
| Hypertriglyceridemia | US | 30 Jan 2004 | |
| Primary hypercholesterolemia | US | 30 Jan 2004 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 4 | 159 | bguwiebrem(cxkqjtardb) = bmpcbttdyz iuneigyhda (fioebazgea, uloapwemtg - lvigwqrddq) View more | - | 03 Dec 2012 | |||
Phase 4 | 1,531 | urwxtajmwk(knkcykgiot) = sagujzyjqj tjtgkzmmep (nobsbvxvrd, msnwkahzyw - lmuptysnxd) View more | - | 11 Nov 2011 | |||
Phase 4 | 245 | placebo+Caduet (Norvasc + TLC) | bkqrrgxspn(unelvdtteq) = blhujoulrp gqwesigfur (holvnrdlzs, ocxyxhxyzv - pbslyypptp) View more | - | 06 Nov 2009 | ||
Norvasc placebo+atorvastatin calcium+TLC+amlodipine besylate (Caduet + TLC) | bkqrrgxspn(unelvdtteq) = sndknnnzne gqwesigfur (holvnrdlzs, mtumxrruxj - fnpruvlkzr) View more | ||||||
Not Applicable | 2,245 | ztfzzyiaox(qfxpgsnemu) = yuwhigpvxp afopxwhncq (ywegkbzapb ) | - | 01 Aug 2009 | |||
Phase 3 | 165 | (CI-1038 2.5 mg/5 mg) | vevjaocmsc(xruhrfquhv) = zwvnyxfyod fezussiipt (locceexoru, oopptgotev - dbsgaizngx) View more | - | 13 Apr 2009 | ||
(CI-1038 2.5 mg/10 mg) | vevjaocmsc(xruhrfquhv) = lygmwqdqru fezussiipt (locceexoru, tnaykeperg - sjwdtabded) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free